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THEMED ARTICLE y CNS neoplasms
From survival to survivorship:  
late side effects become an issue  
in high-grade glioma
Expert Rev. Neurother. 10(10), 1493–1495 (2010)
“For many patients, controlling neurological symptoms, 
preventing cognitive dysfunction and maintaining functional 
independence are just as important as prolonging survival.”
Gliomas are the most common primary 
brain tumors. In adults, the most frequent 
subtype is glioblastoma, an aggressive and 
lethal tumor characterized histologically 
by frequent mitoses, rich angiogenesis and 
necrosis. Multimodality treatment is the 
standard of care: maximal safe resection fol-
lowed by partial brain irradiation combined 
with temozolomide. Resection followed by 
radiation produces a median survival of 
2–3 years in anaplastic astro cytoma [1], 
but only 5–12 months in patients with 
glioblastoma, depending on the popula-
tion studied [2]. The addition of temozolo-
mide, while only increasing median sur-
vival by 2.5 months [3], produces a marked 
increase in long-term survival, with 9.8% 
of patients who received combination treat-
ment living 5 years, as opposed to 1.9% 
with radiation alone [4]. Longer survival is 
associated with host factors (performance 
status and age [5]), molecular character-
istics (O6-methylguanine-DNA methyl-
transferase [MGMT] methylation [6], 
isocitrate dehydrogenase mutations [7] and 
poly morphisms in DNA repair enzymes [8]), 
and treatment factors (more radical resec-
tion [9] and use of temozolomide [4]). The 
cardinal non-molecular factors have been 
combined to define the Radiation Therapy 
Oncology Group (RTOG) recursive 
partitioning ana lysis class [5]. 
There is circumstantial evidence that 
survival may be improving further – in 
recent single-arm trials run by the New 
Approaches to Brain Tumor Therapy 
Consortium, median survival was nearly 
20 months [10]. Whether this survival 
increase is a reflection of the activity of 
the various therapeutic agents tested, the 
results of a more aggressive approach, the 
increased use of second- and third-line 
treatments or some other factor is not clear. 
The expectation is that newer therapies will 
further lengthen survival. As glio blastoma 
shifts from being a rapidly fatal to slowly 
progressive disease, we are obligated to con-
sider the long-term side effects of present 
and future treatments. In addition to the 
‘classical’ side effects, such as neurological 
deficits and brain necrosis, research now 
emphasizes neurocognitive function and 
quality of life. These ‘newer’ end points 
are complex, since both the tumor and the 
treatment impact upon them.
The long-term effects of radiation on 
the brain have been well described [11–14]. 
Pathological changes range from transient 
demyelination to irreversible vascular 
damage with resultant necrosis. A recent 
meta-ana lysis suggested that the brain 
is able to tolerate high doses of ionizing 
radiation (approximately 70 Gy) before 
undergoing necrosis [15]; however, more 
subtle cognitive changes occur at lower 
doses. Memory deficits following irra-
diation follow a biphasic pattern – in the 
initial months an initial decrement with 
rebound, followed by a secondary perma-
nent decline [16–18]. Radiation-induced 
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neurocognitive impairment is especially noted in children [19–21] 
and patients with primary CNS lymphoma [22–24], possibly 
reflecting the use of neurotoxic methotrexate in the latter. 
Cytotoxic chemotherapy alone may also induce cognitive 
impairment. This is best documented in breast cancer patients 
receiving adjuvant adriamycin-based chemotherapy [25,26]. 
Although impairment is generally subtle and intermittent on 
objective testing [27], a subset of patients exhibit more pro-
found and sustained impairment [26]. Consequently, a poten-
tial concern is that temozolomide may be lengthening sur-
vival, but worsening neurocognitive function and quality of 
life. Reassuringly, there is evidence that this is not the case, 
at least for early time points: in a trial of temozolomide for 
recurrent glioblastoma, individuals who were progression-free 
on temozolomide at 6 months had improvement in quality of 
life [28]. Another study demonstrated that amongst patients with 
glio blastoma, temozolomide treatment is associated with pro-
longed functional independence [29]. Furthermore, the European 
Organization for Research on Treatment of Cancer/National 
Cancer Institute of Canada Phase III trial that established temo-
zolomide as standard of care in grade IV gliomas on the basis of 
improved survival also assessed seven domains of health-related 
quality of life (HRQOL; fatigue, insomnia, emotional func-
tion, social function, future uncertainty, communication defi-
cit and overall HRQOL) [30]. Variations during treatment and 
follow-up were not substantial; however, they nearly all showed 
some improvement. Overall there was little difference between 
the radiation alone and the combined radiation–temozolomide 
arms; subjects on the experimental arm experienced more gastro-
intestinal symptoms early on, but this was to be expected and 
quickly improved following the cessation of temozolomide. 
Unfortunately the study had two limitations: firstly, due to 
dwindling numbers, only HRQOL data from the first year of 
follow-up was analyzed; secondly, neurocognitive function was 
not formally tested during follow-up. However, there is some 
preliminary evidence that glioblastoma patients who survive for 
more than 3 years may fare less well, with 85% having at least 
one significant neurologic deficit [31].
Little is known about the long-term neurocognitive side effects 
of novel molecular targeting agents, such as monoclonal antibod-
ies, small molecular inhibitors and immunotherapy. Interestingly, 
early phase clinical trial data suggest that bevacizumab (VEGF 
antibody) can stabilize neurocognitive function and reduce reli-
ance on steroids, improving day-to-day life for patients with 
recurrent glioblastoma [32]. 
Treatment side effects amongst glioma sufferers may not 
only be unpleasant, they may also impinge upon prognosis. By 
analyzing the side effects experienced by subjects previously 
enrolled on RTOG high-grade glioma trials, we were able to 
define risk factors for both acute (age greater than 50 years, poor 
performance status, more aggressive surgery, poor neurological 
function, poor mental function and twice-daily radiation) and 
chronic (once-daily radiation, use of chemotherapy, previous 
acute neurologic toxicity and total radiation dose) neurologic 
toxicity. The presence of acute neurologic toxicity was also found 
to predict poor overall survival, independent of recursive par-
titioning ana lysis class (median survival 7.8 vs 11.8 months; 
p < 0.0001) [33].
We do not know what the impact of new experimental 
agents on normal tissue function will be, whether used alone 
or together with radiation therapy. International coopera-
tive groups led by the European Organization for Research 
on Treatment of Cancer and the RTOG have led the way in 
incorporating quality of life and neurocognitive end points into 
clinical trials; unfortunately, only a proportion of patients seen 
in the clinic are typically eligible for such trials. Only by bring-
ing neuropsychological testing into daily practice will we be 
able to capture information on ‘real patients’ (those with poor 
performance status, elderly, ethnic minorities) that rarely enroll 
onto clinical trials. Standardized neuropsychological tests are 
reliable and valid measures when used correctly. When select-
ing neuropsychological tests, it is recommended to focus on 
specific domains of functioning, such as short-term memory; 
that tests be re-administered repeatedly in order to estimate 
variance and account for the ‘training effect’; and finally that 
only standardized tests with documented reliability and valid-
ity are chosen [34]. Although formal neuropsychological tests 
are considered to be the ‘gold standard’, the associated logisti-
cal costs and staff training required hamper their widespread 
adoption. Computerized testing, such as provided by CogState® 
(CogState Ltd, Melbourne, Australia), may help overcome these 
hurdles [35].
“Little is known about the long-term 
neurocognitive side effects of novel molecular 
targeting agents, such as monoclonal antibodies, 
small molecular inhibitors and immunotherapy.”
Patients with high-grade gliomas desperately require more effec-
tive interventions. For many patients, controlling neurological 
symptoms, preventing cognitive dysfunction and maintaining 
functional independence are just as important as prolonging sur-
vival. As new innovative therapies that seek to extend survival in 
this devastating disease are investigated, it is critical that we also 
evaluate their possible negative impact on functional outcomes 
over the long-term.
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